PM
ADCT icon

Prosight Management’s ADC Therapeutics ADCT Stock Holding History

Prosight Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.37M Sell
7,824,749
-475,251
-6% -$1.39M 1.44% 17
2026
Q1 		$31.1M Sell
8,300,000
-177,338
-2% -$699K 5.1% 8
2025
Q4 		$29.9M Buy
8,477,338
+1,005,035
+13% +$4.08M 6.18% 4
2025
Q3 		$29.9M Sell
7,472,303
-2,995,468
-29% -$9.44M 6.97% 3
2025
Q2 		$28.1M Buy
10,467,771
+924,767
+10% +$1.95M 6.84% 4
2025
Q1 		$13.5M Buy
9,543,004
+28,004
+0.3% +$47.6K 4.42% 8
2024
Q4 		$18.9M Sell
9,515,000
-121,237
-1% -$317K 5.23% 6
2024
Q3 		$30.4M Buy
9,636,237
+66,237
+0.7% +$209K 7.47% 1
2024
Q2 		$30.2M Buy
9,570,000
+2,519,700
+36% +$10M 9.04% 2
2024
Q1 		$31.7M Buy
7,050,300
+578,500
+9% +$2.13M 8.81% 2
2023
Q4 		$10.7M Buy
6,471,800
+1,069,759
+20% +$987K 4.31% 8
2023
Q3 		$4.85M Sell
5,402,041
-181,859
-3% -$242K 1.54% 22
2023
Q2 		$12M Buy
5,583,900
+2,326,540
+71% +$5.23M 3.51% 12
2023
Q1 		$6.35M Buy
3,257,360
+2,794,050
+603% +$10.3M 3.01% 13
2022
Q4 		$1.78M Buy
463,310
+215,680
+87% +$862K 0.97% 25
2022
Q3 		$1.19M Buy
+247,630
New +$1.79M 0.64% 32

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prosight Management's ADCT Position: Q2 2026 in Review

Prosight Management reduced its ADC Therapeutics (ADCT) stake by 5.7% in Q2 2026, selling an estimated $1.39M and leaving 7,824,749 shares worth $8.37M. The position accounts for 1.44% of the portfolio, ranked #17.

Prosight Management first reported a position in ADCT in Q3 2022 and has held it in 16 quarters since. The position peaked at $31.7M in Q1 2024. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Prosight Management held 7,824,749 shares of ADC Therapeutics worth $8.37M as of Q2 2026.
  • Prosight Management sold 475,251 ADC Therapeutics shares in Q2 2026, an estimated $1.39M.
  • ADC Therapeutics made up 1.44% of Prosight Management's portfolio in Q2 2026, its #17 holding.
  • Prosight Management first reported a position in ADC Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Prosight Management's ADC Therapeutics position peaked at $31.7M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.